Prostanoids (including endoperoxides, classical prostaglandins, thromboxanes and prostacyclin) constitute a group of endogenous substances of considerable biological potency. These substances are formed by metabolism of unsaturated fatty acids (Figure 1 ). Well established properties of prostaglandins (POs) include intense vasomotor activity; effects on gastrointestinal, bronchial and uterine smooth muscle; as well as actions on the platelet system (Horrobin 1978) . With such a pharmacological profile, it is perhaps inevitable that attention has been directed towards implicating these compounds as mediators of allergic responses. For instance, it has been suggested that prostaglandins may be involved in permeability changes in local reactions of cutaneous anaphylaxis (Williams & Morley 1973) , bronchoconstriction following antigen challenge in type 1 hypersensitivity (Piper & Vane 1971) ,and in gut allergy (Buisseret et al. 1978) . In 1971 aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) were shown to be potent inhibitors of the enzyme cyclo-oxygenase, the pivotal enzyme for production of various prostaglandins from arachidonic acid (Vane 1971) . This observation implies that prostaglandins could serve only a subsidiary role as end organ mediators, because NSAIDs were known to have little effect on either humoral or cellular manifestations of the immune response. However, evidence continued to accumulate indicating the production of various PO-like materials during allergic responses (Piper & Vane 1969) and of modification of arachidonic acid metabolism by such procedures as sensitization and antigen challenge (Boot et al. 1977) . Such observations are difficult to reconcile with the failure of the NSAIDs markedly to affect allergic responses in either animals (Paul et al. 1978) or man. One particularly striking property of prostaglandins (notably POEt and POE 2 ) is their potency as activators of adenylate cyclase in a number of in vitro systems (Bergstrom 1967) . It is presumably this property which underlies the capacity of these materials to serve as inhibitors of the secretory activity of diverse cell types, for in many situations elevation of cyclic AMP by adenylate cyclase activation is associated with suppression of secretion. This paper reviews experimental evidence implicating a modulatory role for prostaglandins in Type I (immediate hypersensitivity) and Type IV (delayed hypersensitivity) allergic responses ( Figure 2 ). Type 1 allergic reactions (anaphylactic responses) Prostaglandin E 1 and prostaglandin E 2 decrease secretion of anaphylactic mediators in a dose-related manner and this action is mirrored by changes in intracellular cyclic AMP (Lichtenstein 1973 , Tauber et al. 1973 . There is a good correlation between the rank order of potency of prostaglandins A, B, E and F as inhibitors of histamine release from leukocytes and as stimulators of cyclic AMP production (Lichtenstein 1973) .
The question arises as to which cells involved in Type I hypersensitivity reactions might be able to produce adequate concentrations of E-type prostaglandins so as to effect an inhibition of mediator secretion. During in vitro culture, human alveolar macrophages have been shown to produce PG E 2 and thromboxane B 2 (Morley et al. 1979) , and in similar conditions purified rat mast cells generate significant amounts of E-type prostaglandin (Tolone et al. 1978 ). These cell types may contribute to the production of prostaglandin by lung tissue in response to antigenic stimulation (Dawson et al. 1976) . Studies with haematogenous cells have also shown that eosinophils and neutrophils spontaneously produce PGE 2 , but only in relatively modest amounts (Morley et al. 1979) . Although Hubscher (1975) has claimed that antigen-stimulated eosinophils form PG-like material in amounts sufficient to suppress mediator secretion from human basophils, it remains to be demonstrated unequivocally which cell types increase their PG secretion in response (directly or indirectly) to antigen stimulation.
Indomethacin enhances allergic mediator secretion in a number of experimental models of Type I hypersensitivity (Walker 1972 , Engineer et al. 1978 , Marone et al. 1979 , an effect presumed to be related to the potency of this drug as an inhibitor of cycle-oxygenase. On this basis, NSAIDs, such as indomethacin, could increase mediator release by two different mechanisms. Firstly, SRS-A formation could be enhanced by diversion of arachidonic acid metabolism into the lipoxygenase pathway ( Figure 1) ; secondly, absence of PGE 2 formation might be anticipated to enhance secretion of mediators, such as histamine, from storage granules in the mast cells. It is possible that these two processes operate in concert, in that SRS-A potentiates responses to histamine (Orange & Austen 1969) and serves to induce formation of prostaglandins which possess similar properties. The relative contribution of these processes remains poorly defined even for in vitro situations, for the chemical character of SRS-A (Morris et al. 1980 ) and other slow-reacting substances, such as leucotriene C (Murphy et al. 1979) , is only now becoming evident. An interesting prediction is that manoeuvres increasing SRS-A formation need not necessarily be paralleled by equivalent changes in histamine secretion.
On the basis of the foregoing explanation, indomethacin could be expected to enhance in vivo manifestations of Type I hypersensitivity. However, in a study of the effect of nonsteroidal anti-inflammatory drugs administered locally in lesions of Type I hypersensitivity, it was apparent that the effect of these drugs was generally one of modest inhibition, and in no instance was any enhancement of the response observed (Paul et al. 1978) . Studies on antigeninduced bronchospasm in the guinea-pig have reported partial suppression by NSIADs, or enhancement (Collier et al, 1968 , Miller & Robson 1976 . In assessing in vivo evidence it should be noted that in addition to the loss of action of endogenous PGs in regulating mediator secretion, there is also the loss of the interaction between PGs and mediators in the spasmogenic component of anaphylaxis. For instance, anaphylaxis in the lung involves release of substances, including SRS-A, which cause PG generation, whilst in skin PGE 2 is a powerful potentiator of the action of endogenous materials causing increased vascular permeability (e.g. histamine and complement). These effects may quantitatively overshadow any anti-aIlergy action of the PGs, and could account for the modest inhibitory effects of NSAIDs on aIlergic responses in vivo.
Although the physiological evidence invivo provides only limited support for PGs regulating Type I hypersensitivity, there is at least one clinical observation which is consistent with'such a role. Thus, aspirin-sensitive asthma (ASA) is a well defined clinical entity in which bronchospasm can be induced by ingestion or inhalation of aspirin. Of particular interest is the clear evidence that bronchospasm can similarly be induced in these subjects by other NSAIDs and that their rank efficacy in inducing bronchospasm corresponds to their potency as inhibitors of PG synthesis (Szczeklik et al. 1975 ). Hence, it has been suggested that endogenous PG production suppresses allergic mediator secretion and that aspirin induces bronchospasm by abolishing this control. Alternatively, NSAIDs may divert arachidonic acid metabolism along the lipoxygenase pathway, with a consequent increase in SRS-A production. However, the failure to identify cellular elements responsible for the formation of arachidonic acid products in such responses has limited the extent of analysis. The participation in such processes of less well studied agents, such as thromboxane A 2 , prostaglandin D 2 or prostaglandin 12, would seem to be of considerable potential interest, but as yet remains largely undefined.
Type IV allergic reactions (delayed hypersensitivity)
The response of delayed hypersensitivity is attributable to activation of lymphocytes, particularly of thymus-dependent lymphocytes. Certain high molecular weight glycoprotein products of these cells have been designated lymphokines, and it is well established that both the process oflymphocyte activation, and that oflymphokine secretion by these cells, may be inhibited by low concentrations of prostaglandin E I and E 2 . In contrast to the antibody mediated responses, it has proved possible in this situation to identify the macrophage as a likely source of endogenous prostaglandin which might inhibit lymphocyte activation, since these cells produce substantial amounts of prostaglandin E 2 in short-term culture (Bray et al. 1974) . Moreover, it has been shown that PGE 2 production can be directly stimulated. by preformed lymphokines in the absence of the lymphocyte (Gordon et al. 1976) .
It is thus possible that, following antigen activation, released lymphokine will, in turn, activate macrophages to form PGE 2 as an inhibitor of lymphocyte activation (Figure 3) . This negative feedback system has been suggested as a device for regulating the extent and duration of lymphocyte activation in delayed hypersensitivity reactions (Gordon et al. 1976 This relationship has been analysed in some detail in the guinea-pig and more recently has been shown to be evident in human cell populations using tonsillar lymphocytes (Lomnitzer et al. 1976) . In human studies the cellular origin of PGE 2 is less certain and it has been suggested that in peripheral blood the cell involved is a glass-adherent lymphocyte (Goodwin et al. 1977a) .
As in Type I hypersensitivity, the implication of this regulatory device is that indomethacin should enhance the secretion oflymphokine, a phenomenon that can be shown to occur invitro using guinea-pig (Gordon et al. 1976) or human cells (Goodwin et al. 1977b) . This relationship of macro phages to lymphocytes via PGE has interesting implications which have a bearing on a number of clinical conditions. Thus, in chronic inflammation, a loss of reactivity to E-type prostaglandin could result in the over-production of lymphokines, lysosomal enzymes, collagenase and E-type prostaglandins as a consequence of a single event, lymphocyte activation (Morley 1974) . Evidence of such defective reactivity, in a restricted population of lymphocytes, has been reported for patients with active multiple sclerosis (Kirby et al. 1976) , though other studies, in rheumatoid arthritis, have suggested that if such defective reactivity occurs it is restricted to cells within a lesion (Zurier et al. 1977 ). An alternative proposition is that over-production of E-type prostaglandin would have a suppressive effect on lymphocytes resulting in impaired immunological reactivity. Evidence has been presented that such a process underlies the impaired lymphocyte reactivity observed in Hodgkin's disease (Goodwin et al. 1977b) and that, to a lesser extent, this can account for impaired reactivity in sarcoidosis. The evidence supporting this viewpoint is that: (1) peripheral blood cultures from such individuals produced increased amounts of E-type prostaglandin;
(2) indomethacin reverses the impaired lymphocyte reactivity in vitro; and (3), in certain cases of immunodeficiency, treatment of patients with indomethacin can restore some reactivity to antigens as judged by delayed hypersensitivity reactions in skin. From the standpoint of pharmacology, this relationship raises particularly interesting questions, since it should be apparent that NSAIDs, while affording symptomatic relief by elimination of PG production, could at the same time be exacerbating the disease process if this is attributable to lymphocyte activation. There is certainly ample direct evidence in experimental models of inflammation that PGE, can exert an inhibitory action, a phenomenon that is particularly evident in essential fatty acid deficient animals (Bonta & Pamham 1979) .Corresponding evidence of an anti-inflammatory action of PGs is not available in man, but observations exist to suggest that PGs can exert such an effect in human tissue. Thus, whilst indomethacin suppresses PO production by synovial explants, the production of collagenase can paradoxically be enhanced (Dayer et al. 1978 ). Further, it is possible that POs exert a regulatory action on lymphocytes in chronic inflammatory diseases of the large intestine, since sulphasalazine, which is used in the treatment of ulcerative colitis and Crohn's disease, has been shown to inhibit prostaglandin dehydrogenase (Hoult & Moore 1978) and, by implication, prostaglandin breakdown.
Conclusion
Although much attention has been, and continues to be, directed at prostaglandin actions as mediators of pathological processes, it has become increasingly evident that these materials playa significant role as regulators of mediator secretion in allergic reactions. It seems likely that analysis of the actions of prostaglandins on allergic phenomena will aid our insight into the mechanisms of diseases involving aberrant allergic responses and that advantage may be taken of this regulatory action of prostaglandins in the development of new classes of antiallergic agents.
